Updated on 30 July 2013
Mr Olivier Brandicourt will lead the transition from the current organization to the new structure; Mr Douglas Lankler will become general counsel; and Ms Rady Johnson will become chief compliance and risk officer
Singapore: Pfizer is going to separate its commercial operations into three business segments, two of which will include innovative business lines and a third that will include the value business line. Each of the three segments will include developed markets and emerging markets.
The changes will be implemented in January 2014 in countries that do not require a consultation with works councils or unions, and will be implemented in countries that require consultation after the successful conclusion of those processes. Beginning with the first-quarter 2014 financial results, the company will provide financial transparency for each of these three business segments, which will include a 2014 baseline management view of profit and loss for each segment.
One of the innovative business segments will be led by Mr Geno Germano, group president, Innovative Products Group. It will generally include products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015. The therapeutic areas include inflammation and immunology, cardio vascular/metabolic, neuroscience and pain, rare diseases and women's and men's health.
The other innovative business segment will include vaccines, oncology and consumer healthcare and will be led by Ms Amy Schulman, group president, Vaccines, Oncology and Consumer Healthcare. Each of these businesses will operate as a separate global business and require distinct specialization in terms of the science, talent, and market approach required to deliver value to consumers and patients.
The value business segment will be led by Mr John Young, group president, Value Products Group. This group will include products that generate strong, consistent cash flow, and will be positioned to provide patients access to effective, lower-cost, high-value treatments. In addition to products that have lost market exclusivity, it will generally include mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets, biosimilars and current and future established products collaborations, such as the existing partnerships with Mylan in Japan, Teuto in Brazil and Hisun in China.